CCCC news

Latest 1 stories · newest Nov 5, 2026

CCCC

C4 Therapeutics reports Q3 2026 financials and updates on development programs

C4 Therapeutics reported third quarter financial results and highlighted recent achievements in Phase 2 MOMENTUM and Phase 1b trials, showing progress towards data publication in late 2026 and enrollment goals for 2027, which underscores ongoing clinical advancement for its cemsidomide candidate.

Earnings Nov 5, 2026 sentiment +0.20 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same CCCC feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/CCCC/newsSTART FREE